ArticleVirulence2026
Serology survey against multiple SARS-CoV-2 variants of residents in Tainan, Taiwan.
Article in Virulence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its evolving variants, continues to challenge global efforts to control its spread. Ongoing mutations may enhance transmissibility or lead to breakthrough infections, making immune monitoring crucial for public health policies.
methodsA SARS-CoV-2 variant protein microarray was used to assess total and neutralizing antibodies against multiple variants. A serological survey was conducted in October 2022 in Tainan, Taiwan, including general citizens and special medical care groups. The general population comprised residents from the city (n = 504), suburban (n = 166), and country areas (n = 88). Special groups included individuals in elderly care centers (n = 50), nursing homes (n = 51), kidney dialysis patients (n = 100), and people living with human immunodeficiency virus (PLWH) (n = 45). Statistical analyses were performed using one-way and repeated-measures analysis of variance (ANOVA).
resultsThe results demonstrated that the neutralization efficacy against Omicron and its subtypes declined according to the evolution of the variants, particularly in city and suburban areas. Special medical care populations, including individuals in elderly care centers, nursing homes, those undergoing kidney dialysis, and those PLWH, exhibited lower neutralization effectiveness. After analyzing the infection status, it can be found that special medical care populations had higher infection rates, especially in elderly care centers and nursing homes.
conclusionsSARS-CoV-2 protein microarray analysis is essential for assessing immunity at a population level. The findings highlight the need for adjusted vaccination strategies and ongoing surveillance of humoral immunity to address emerging SARS-CoV-2 variants effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.